Multiple sclerosis progression: time for a new mechanism-driven framework
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …
relapsing-remitting, secondary progressive, and primary progressive—for patient care …
Myelin in the central nervous system: structure, function, and pathology
C Stadelmann, S Timmler… - Physiological …, 2019 - journals.physiology.org
Oligodendrocytes generate multiple layers of myelin membrane around axons of the central
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …
Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis
C Tur, P Carbonell-Mirabent, Á Cobo-Calvo… - JAMA …, 2023 - jamanetwork.com
Importance Progression independent of relapse activity (PIRA) is the main event responsible
for irreversible disability accumulation in relapsing multiple sclerosis (MS). Objective To …
for irreversible disability accumulation in relapsing multiple sclerosis (MS). Objective To …
High-efficacy therapies for treatment-naïve individuals with relapsing–remitting multiple sclerosis
There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …
action currently approved by the US Food and Drug Administration for the treatment of …
Multiple sclerosis: clinical aspects
A number of recent advances have been made in the clinical diagnosis and prognostication
of multiple sclerosis patients. Future research will enable the development of more accurate …
of multiple sclerosis patients. Future research will enable the development of more accurate …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
Neuro-axonal injury is a key factor in the development of permanent disability in multiple
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …
The role of natural killer cells in autoimmune diseases
Natural killer (NK) cells, the large granular lymphocytes differentiated from the common
lymphoid progenitors, were discovered in early 1970's. They are members of innate …
lymphoid progenitors, were discovered in early 1970's. They are members of innate …
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - Springer
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …